Drug substance for the ALZ-101 vaccine is now produced – meets the requirements of the upcoming clinical Phase 1b studyDate: 2021-01-08
Alzinova AB has secured materials for the clinical Phase 1b study through the manufacturing of the drug substance for the oligomer-specific vaccine ALZ-101. The high-purity material meets the quality requirements of the clinical trial. The clinical trial with ALZ-101 on Alzheimer's disease patients is expected to start during the second quarter of 2021.
“We are very pleased that the drug substance for the upcoming clinical Phase 1b study with ALZ-101 is now manufactured. For us, this is an important milestone, showing that the drug substance for the ALZ-101 vaccine can be manufactured to a good quality for clinical trials. This important information allows us to look forward to the further preparations for initiating the first clinical study with this therapeutic vaccine in Alzheimer's disease patients during the second quarter of 2021,” says Kristina Torfgård, CEO.
For more information, please contact:
Kristina Torfgård, CEO
Telephone: +46 70 846 79 75
The information was submitted for publication, through the agency of the contact person set out above, at 08.01 CET on January 8, 2020.
About Alzinova AB
Alzinova AB is a Swedish biopharma company specializing in the treatment of Alzheimer’s disease by targeting neurotoxic amyloid-β oligomers. The lead candidate, ALZ-101, is in late preclinical development as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid-β oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201, in early preclinical development, was generated with the AβCC peptide™ technology and the ambition is to expand the pipeline further. The Company’s Certified Advisor on Nasdaq First North is Corpura Fondkommission AB, email@example.com, +46 (0)768-532 822. For more information about Alzinova, please visit: www.alzinova.com